Abcam, ab223259, Anti-Cytokeratin 19 antibody

Size: 100µg
Goat Polyclonal Cytokeratin 19 antibody. Suitable for WB, IHC-P and reacts with Human samples. Cited in 1 publication. Immunogen corresponding to Synthetic Peptide within Human KRT19 aa 250-300.
Key facts
Host species:Goat,
Clonality:Polyclonal,
Isotype:IgG,
Carrier free:No,
Reacts with:Human,
Applications:WB, IHC-PSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:Synthetic Peptide within Human KRT19 aa 250-300. The exact immunogen used to generate this antibody is proprietary information.P08727

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Immunogen, Storage buffer-pH: 7.3 Preservative: 0.02% Sodium azide Constituents: Tris buffered saline, 0.5% BSA, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Cytokeratin 19 (CK19) also known as cytokera­tine 19 keratin 19 (KRT19) or CK19 is a type of intermediate filament found in epithelial cells. It serves as an essential component of the cytoskeleton. CK19 weighs approximately 40 kDa and is broadly expressed in simple epithelial tissues including liver intestine and various glandular epithelial cells. As a cytokeratin marker it often appears in combination with others like cytokeratin 17 in certain tissue types helping to maintain the structural integrity of cells.
Biological function summary
CK19 plays a role in maintaining the cytoskeletal framework that provides mechanical support and helps control cell size and shape. It is not part of a large protein complex but works closely with other cytokeratins to ensure the stability and resilience of epithelial tissues. The A53-B/A22.26 positive staining is often used to confirm its presence in clinical histopathology.
Pathways
CK19 connects to cellular processes especially involving the keratinization and epithelial cell differentiation pathways. It interacts with other cytokeratins including BA16 and KR17 to facilitate these processes. This interaction aids in modulating the dynamics of cytoskeletal rearrangement during cell movement division and differentiation.
CK19 overexpression is linked with certain cancers notably hepatocellular carcinoma and breast cancer. It can serve as a prognostic marker in these diseases often in conjunction with other markers like CK17. The involvement of CK19 in the epithelial-mesenchymal transition (EMT) process connects it to the progression and aggressiveness of tumors facilitated by interactions with proteins involved in EMT pathways.